CD4+ T Cell Immune Specificity Changes After Vaccination in Healthy And COVID-19 Convalescent Subjects

The immune response promoted by SARS-CoV-2 vaccination is relevant to develop novel vaccines and optimized prevention strategies. We analyzed the adaptive immunity in healthy donors (HD) and convalescent individuals (CD), before and after administering BNT162b2 vaccine. Our results revealed specific...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 12; p. 755891
Main Authors Esparcia-Pinedo, Laura, Martínez-Fleta, Pedro, Ropero, Noelia, Vera-Tomé, Paula, Reyburn, Hugh T., Casasnovas, José M., Rodríguez Frade, José M., Valés-Gómez, Mar, Vilches, Carlos, Martín-Gayo, Enrique, Muñoz-Calleja, Cecilia, Sanchez-Madrid, Francisco, Alfranca, Arantzazu
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 19.01.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The immune response promoted by SARS-CoV-2 vaccination is relevant to develop novel vaccines and optimized prevention strategies. We analyzed the adaptive immunity in healthy donors (HD) and convalescent individuals (CD), before and after administering BNT162b2 vaccine. Our results revealed specific changes in CD4+ T cell reactivity profile in vaccinated HD and CD, with an increase in S1 and S2 positive individuals, proportionally higher for S2. On the contrary, NCAP reactivity observed in HD and CD patients was no longer detectable after vaccination. Despite the substantial antibody response in CD, MPro-derived peptides did not elicit CD4+ lymphocyte activation in our assay in either condition. HD presented an increment in anti-S and anti-RBD IgG after first dose vaccination, which increased after the second vaccination. Conversely, anti-S and anti-RBD IgG and IgA titers increased in already positive CD after first dose administration, remaining stable after second dose inoculation. Interestingly, we found a strong significant correlation between S1-induced CD4+ response and anti-S IgA pre-vaccination, which was lost after vaccine administration.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Reviewed by: Kwong Tsang, Precision Biologics, Inc., United States; Roopali Rajput, National Institute of Tuberculosis and Respiratory Diseases, India
Edited by: Katie Louise Flanagan, RMIT University, Australia
These authors have contributed equally to this work and share first authorship
This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2021.755891